Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a
BELLINGS Intelligence Score: 8
Why it matters
This is a routine collaboration announcement in the biotech/clinical testing sector with no direct impact on credit markets, underwriting, or regulatory frameworks relevant to sophisticated credit professionals.